Loading...
XHKG
2291
, Last price  
HKD
Name

Lepu Scientech Medical Technology Shanghai Co Ltd

Chart & performance

D1W1MN
XHKG:2291 chart
P/E
—
P/S
—
EPS
0.69
Vol. 1Y
—
Shs. 5Y
4.58%
Rev. 5Y
28.92%
Div Yld LY
—
Div Yld TTM
—
Revenues
528m
+11.94%
116,451,000148,247,000222,583,000247,670,000325,896,000471,644,000527,944,225
Net income
240m
-2.38%
51,909,00068,772,00058,697,000-19,813,000151,532,000245,560,000239,727,928
CFO
221m
-0.63%
54,475,00059,097,000105,278,00065,531,000164,257,000222,486,000221,095,230
Dividend
May 27, 20260.57255 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding entity, focuses globally on the research, development, production, and marketing of advanced interventional medical devices. The company provides an extensive range of solutions addressing various cardiovascular ailments. This includes specialized treatments for congenital heart defects, such as occluders for atrial septal, ventricular septal, and patent ductus arteriosus, along with necessary delivery systems and snare products. Additionally, it develops technologies for preventing cardioembolic stroke, offering occluders for the left atrial appendage and patent foramen ovale. Its portfolio also features a comprehensive selection of products for managing valvular diseases, including devices for aortic, mitral, tricuspid, and pulmonary valves, complemented by essential procedural accessories. Further offerings encompass vascular plugs and interatrial shunt devices. These medical technologies are primarily distributed to hospitals and through a network of distributors. Founded in 1994, the firm is headquartered in Shanghai, People's Republic of China, and operates as a subsidiary of Lepu Medical Technology (Beijing) Co., Ltd.
IPO date
Nov 08, 2022
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT